{rfName}

Indexed in

License and use

Licencia
Icono OpenAccess

Altmetrics

Grant support

We thank Daiichi Sankyo for their provision of patritumab deruxtecan and their financial contribution to this clinical study. Pas a Pas and Save the Mama to AP. Fundacion SEOM (SEOM 2018 Grant: Fellowship for Training in Research in Reference Centers) to TP.

Analysis of institutional authors

Vidal Rodriguez, MartaAuthorPascual TAuthorMunoz MAuthorVidal MjAuthorCejalvo JmAuthorGonzalez-Farre BAuthorMartínez-Sáez OAuthorPrat ACorresponding Author

Share

Publications
>
Article

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Publicated to:Frontiers In Oncology. 11 638482- - 2021-04-23 11(), DOI: 10.3389/fonc.2021.638482

Authors: Pascual, Tomas; Oliveira, Mafalda; Ciruelos, Eva; Bellet Ezquerra, Meritxell; Saura, Cristina; Gavila, Joaquin; Pernas, Sonia; Munoz, Montserrat; Vidal, Maria J; Margeli Vila, Mireia; Cejalvo, Juan M; Gonzalez-Farre, Blanca; Espinosa-Bravo, Martin; Cruz, Josefina; Salvador-Bofill, Francisco Javier; Guerra, Juan Antonio; Luna Barrera, Ana Maria; Arumi de Dios, Miriam; Esker, Stephen; Fan, Pang-Dian; Martinez-Saez, Olga; Villacampa, Guillermo; Pare, Laia; Ferrero-Cafiero, Juan M; Villagrasa, Patricia; Prat, Aleix

Affiliations

‎ August Pi Sunyer Biomed Res Inst, Inst Invest Biomed August Pi & Sunyer, Translat Genom & Targeted Therapies Solid Tumors, Barcelona, Spain - Author
‎ Biomed Res Inst Fdn Invest Hosp Clin Comunidad Va, Breast Canc Biol Res Grp, Valencia, Spain - Author
‎ Ctr Integral Oncologico Clara Campal, Med Oncol Dept, Madrid, Spain - Author
‎ Daiichi Sankyo Inc, Res & Dev, Basking Ridge, NJ USA - Author
‎ H Bellvitge Inst Invest Biomed Bellvitge, Inst Catala Oncol ICO, Med Oncol Dept, Barcelona, Spain - Author
‎ Hosp 12 Octubre, 6Med Oncol Dept, Madrid, Spain - Author
‎ Hosp Badalona Germans Trias & Pujol, ICO Inst Catala Oncol Badalona, Med Oncol Dept, Badalona, Spain - Author
‎ Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain - Author
‎ Hosp Clin Barcelona, Pathol Dept, Barcelona, Spain - Author
‎ Hosp Clin Univ Valencia, Med Oncol Dept, Valencia, Spain - Author
‎ Hosp Univ Canarias, Med Oncol Dept, Santa Cruz de Tenerife, Spain - Author
‎ Hosp Univ Fuenlabrada, Med Oncol Dept, Madrid, Spain - Author
‎ Hosp Univ Virgen Rocio, Med Oncol Dept, Seville, Spain - Author
‎ IVO Fundac Inst Valenciano Oncol, Med Oncol Dept, Valencia, Spain - Author
‎ SOLTI Innovat Canc Res, Barcelona, Spain - Author
‎ Univ Barcelona, Med Dept, Barcelona, Spain - Author
‎ Vall dHebron Barcelona Hosp, Hosp Univ Vall dHebron, Breast Canc Program, Barcelona, Spain - Author
‎ Vall dHebron Barcelona Hosp, Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain - Author
‎ Vall Hebron Inst Oncol VHIO, Oncol Data Sci, Barcelona, Spain - Author
‎ Vall Hebron Univ Hosp, Breast Canc Surg Unit, Barcelona, Spain - Author
See more

Abstract

Background: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast cancer. Given the need to better understand the molecular biology, tumor microenvironment, and mechanisms of drug resistance in breast cancer, we designed this window-of-opportunity study with the HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402). Trial Design: Based on these data, a prospective, multicenter, single-arm, window-of-opportunity study was designed to evaluate the biological effect of patritumab deruxtecan in the treatment of naive patients with HR-positive/HER2-negative early breast cancer whose primary tumors are >= 1 cm by ultrasound evaluation. Patients will be enrolled in four cohorts according to the mRNA-based ERBB3 expression by central assessment. The primary endpoint is a CelTIL score after one single dose. A translational research plan is also included to provide biological information and to evaluate secondary and exploratory objectives of the study.

Keywords

Breast cancerCáncer de mamaCeltil scoreChemotherapyDocetaxelErbb3ExpressionHer3Her3-dxdHormone receptorsLapatinibMulticenterOpen-labelPatritumab deruxtecanPredictionReceptors d'hormonesSurvivalTrastuzumabTumor-infiltrating lymphocytesU3-1402

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Frontiers In Oncology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.23. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 1.28 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 5.72 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-30, the following number of citations:

  • WoS: 21
  • Scopus: 24
  • Europe PMC: 9

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-30:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 45.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 45 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 15.6.
  • The number of mentions on the social network X (formerly Twitter): 25 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: http://hdl.handle.net/2445/177728

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Pascual Martínez, Tomas) and Last Author (Prat Aparicio, Aleix).

the author responsible for correspondence tasks has been Prat Aparicio, Aleix.